Research Topics
| David T DunnSummaryAffiliation: National Institute for Medical Research Country: UK Publications
| Collaborators
|
Detail Information
Publications
HIV drug resistance testing: is the evidence really there?David T Dunn
MRC Clinical Trials Unit, London, UK
Antivir Ther 9:641-8. 2004..To assess the strength of evidence supporting the routine use of HIV drug resistance testing...
Genotypic resistance testing in routine clinical careDavid T Dunn
MRC Clinical Trials Unit, London, UK
Curr Opin HIV AIDS 6:251-7. 2011..Genotypic resistance testing has become part of routine clinical management of HIV-infected patients. Focussing on observational studies, this review looks at recent advances in this area...- Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysisDavid Dunn
MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
Lancet 362:1605-11. 2003..We estimated 12-month risks of progression to AIDS and death, by age and most recent measurement of CD4 T-cell percentage (CD4%) or viral load, in children receiving no antiretroviral therapy or zidovudine monotherapy only... 
Residual activity of two HIV antiretroviral regimens prescribed without virological monitoringD T Dunn
MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, United Kingdom
Antimicrob Agents Chemother 55:4575-80. 2011..This information should be considered in future treatment guidelines relevant to resource-poor settings...- The dangers of inferring treatment effects from observational data: a case study in HIV infectionDavid Dunn
MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
Control Clin Trials 23:106-10. 2002..Examples such as this emphasize the need to regard randomized controlled trials as the primary mechanism for assessing therapeutic efficacy... - A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: evaluation of resistance assays (ERA) trial investigatorsD T Dunn
HIV Division, Medical Research Council Clinical Trials Unit, London, United Kingdom
J Acquir Immune Defic Syndr 38:553-9. 2005..To assess the clinical utility of phenotypic resistance testing in addition to genotypic resistance testing among HIV-1-infected patients experiencing virologic failure and with limited therapeutic options... - Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adultsDavid Dunn
Medical Research Council Clinical Trials Unit, London, United Kingdom
J Infect Dis 197:398-404. 2008..Currently, there are no comparable estimates of the short-term risk of disease progression in the absence of effective antiretroviral therapy for human immunodeficiency virus (HIV)-infected adults and children... - Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)Diana M Gibb
Medical Research Council Clinical Trials Unit, London, UK
Antivir Ther 7:293-303. 2002.... - Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infectionDiana M Gibb
Medical Research Council Trials Unit, London, UK
Pediatr Infect Dis J 23:446-50. 2004..There are few data on the decline of CD4 cells or percentage during unplanned treatment interruptions in HIV-infected children... - A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trialHannah Green
MRC Clinical Trials Unit, London, UK
Antivir Ther 11:857-67. 2006..To evaluate the longer-term utility of genotypic resistance testing in HIV-1-infected children with virological failure... - The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United KingdomHannah Green
HIV Group, Medical Research Council Clinical Trials Unit, 222 Euston Road, London, United Kingdom
J Acquir Immune Defic Syndr 49:196-204. 2008..The use of different lists of resistance mutations has resulted in estimates of transmitted HIV drug resistance (THDR) that are often not comparable... - Interval-censored survival time data: confidence intervals for the non-parametric survivor functionRuth L Goodall
MRC Clinical Trials Unit, London, UK
Stat Med 23:1131-45. 2004..In a simulation study the likelihood ratio method gave the most accurate confidence intervals with coverage consistently close to the nominal level of 95 per cent... - Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapyAlexander J Frater
Jefferiss Trust Laboratories, Wright-Fleming Institute, Imperial College School of Medicine, St Mary's Campus, London, UK
AIDS 16:1139-46. 2002..On the basis of these findings, there is no justification for withholding HAART from Africa on virological grounds... - Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trialNicholas I Paton
MRC Clinical Trials Unit, Aviation House, 125 Kingsway, London WC2B 6NH, United Kingdom
JAMA 308:353-61. 2012..Therapies to decrease immune activation might be of benefit in slowing HIV disease progression... - HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United KingdomDaniella N Chilton
Medical Research Council Clinical Trials Unit, London, UK
Antivir Ther 15:985-91. 2010..We examined the characteristics of HIV-1 drug resistance in antiretroviral treatment (ART)-naive individuals migrating to the UK... - Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistanceHannah Castro
Medical Research Council Clinical Trials Unit, London, UK
BMC Med Res Methodol 12:30. 2012..However estimates of the prevalence of TDR will also be distorted if some ART-experienced patients are misclassified as ART-naïve... - Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmissionD M Gibb
Medical Research Council Clinical Trials Unit, London, UK
Lancet 356:904-7. 2000..We examined the effect of risk factors, including mode of delivery, on the vertical transmission rate... - Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and IrelandD M Gibb
Medical Research Council Clinical Trials Unit, London NW1 2DA
BMJ 327:1019. 2003..To describe changes in demographic factors, disease progression, hospital admissions, and use of antiretroviral therapy in children with HIV... - Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapyMarietta Charakida
Vascular Physiology Unit, Institute of Child Health, London, UK
Circulation 112:103-9. 2005..The purpose of this study was to determine the impact of HIV infection and antiretroviral therapy (ART) on markers of early vascular disease in children... - Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected childrenK Boyd
Medical Research Council Clinical Trials Unit, London, UK
AIDS 24:1213-7. 2010..This leads to clinical dilemma when one marker is below the threshold, whereas the other is above... - Timing and interpretation of tests for diagnosing perinatally acquired hepatitis C virus infectionD T Dunn
Medical Research Council Clinical Trials Unit, Institute of Child Health, London, UK
Pediatr Infect Dis J 20:715-6. 2001..These estimates may assist clinicians in assessing the likelihood of infection in an individual child and in using the currently available assays cost effectively... - Maternal viral load, CD4 cell count and vertical transmission of HIV-1S O'Shea
Department of Virology, United Medical School, Guy s Hospital, London, United Kingdom
J Med Virol 54:113-7. 1998..High viral load is also associated with premature delivery. Maternal viral load is therefore a useful marker on which to base management decisions during pregnancy... - Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA)Charles F Gilks
Imperial College, London, UK
Antivir Ther 17:1363-73. 2012..Boosted protease inhibitor (bPI) monotherapy (bPImono) potentially has substantial cost, safety and operational benefits. It has never been evaluated as second-line antiretroviral therapy (ART) in Africa... - Transmission network parameters estimated from HIV sequences for a nationwide epidemicAndrew J Leigh Brown
Institute of Evolutionary Biology, University of Edinburgh, London, United Kingdom
J Infect Dis 204:1463-9. 2011..Recent developments in molecular phylodynamics have provided new routes to obtain these parameter estimates, and current clinical practice provides suitable data for entire infected populations... - Modelling the association between patient characteristics and the change over time in a disease measure using observational cohort dataL Harrison
HIV Group and Hub for Trials Methodology Research, MRC Clinical Trials Unit and University College London, 222 Euston Road, London, NW1 2DA, U K
Stat Med 28:3260-75. 2009..Our approach is compared with other methods and illustrated through a simulation study and an analysis of the association between HIV-1 subtype and immunological response after starting antiretroviral therapy... - A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapyH Green
Medical Research Council Clinical Trials Unit, London, UK
HIV Med 5:278-83. 2004..The case of recurrent CMV retinitis in a patient with impressive immunological and virological response indicates the need for close monitoring of patients previously diagnosed with this condition... - What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?D Grover
Centre of Sexual Health and HIV Research, Department of Primary Care and Population Sciences, Mortimer Market Centre, London, UK
J Antimicrob Chemother 61:705-13. 2008..Changing antiretroviral therapy following emergence of MDR HIV-1 may be associated with improved short-term virological response... - Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UKP J Easterbrook
Department of HIV GU Medicine, Kings College London School of Medicine at Guy s, London, UK
HIV Med 9:47-56. 2008..We describe the patterns of antiretroviral drug use at treatment initiation from 1996 to 2005 in a large UK multicentre cohort...